09.11.13 -- What's Next For Disposables in Biomanufacturing?
Discover a new approach to producing wild-type or recombinant viruses used as vaccines and human gene therapy vectors. Some, like lentivirus, paramyxovirus, and adeno-associated-virus (AAV), have demonstrated high potential in modern medicine.
Commonly produced with adherent cell lines in 2D systems, they use either transient transfection or infection strategies. However, these poorly-controlled, labor intensive processes require large areas of cleanroom space and involve high risk of microbial contamination. Learn more about the solution to these challenges developed by ATMI LifeSciences.
By Eric Langer, President and Managing Partner, BioPlan Associates, Inc.
New single-use technologies are seeing greater adoption beyond preclinical and clinical applications and into commercial-scale manufacturing. As biomanufacturers attempt to keep up with the steady increase in expression yields and improve the management of their processes, more — and better — sensors and control equipment are being demanded.
By S. Dubois (ATMI LifeSciences) and K. Lipinski (Vibalogics)
Viral vaccines are usually produced by anchorage-dependent cell lines (e.g. VERO, MRC-5, WI-38, and CEF). At industrial scale, these cells are either cultivated in static mode on multiplate systems, on roller bottles, or on microcarriers (porous or nonporous) in suspension in bioreactors.
By Richard Beeny, Co-Founder and CEO, LifeScience Logistics
In the past, most pharmaceutical companies performed their warehouse and distribution services within their own facilities, with very few outsourcing these processes to third-parties. The supply chain was much simpler then, essentially getting a product from point A to point B.
By Jean Bédard, President and CEO, Infitrak
Delays in product shipments or raw materials not only cause reputational issues, but if your packaging and carriers are not able to monitor or regulate critical temperature ranges, product quality will suffer.